Mednet Logo
CommunityMedical Oncology

Would you give chemotherapy to a post menopausal woman with ER/PR positive HER2 negative breast cancer, T2N1 with 3+ lymph nodes, Ki-67 30% and OncoType RS of 10?

Community PollStarted

What would you offer a post menopausal woman with ER+/PR+/HER2- breast cancer, T2N1 with 3+ nodes, Ki-67 30% and OncoType RS of 10?

91 physicians have voted

Join Mednetto vote and see how they answered.

4 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Icahn School of Medicine at Mount Sinai
Answered on

I would not give this postmenopausal woman adjuvant with a recurrence score of 10 based on RxPONDER trial. In that trial women with recurrence scores of 25 or less were randomized to receive chemotherapy + endocrine versus endocrine therapy alone. The Kaplan Meier curves were superimposable. I would...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Utah Huntsman Cancer Institute
Answered on

I think this is a complicated situation that requires a nuanced approach. We know that clinicopathological features are important, independent of Oncotype RS. I would need to consider age (she is postmenopausal, but there is a difference between a 52-year-old and a 75-year-old), grade, tumor size, %...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology · Private Practice and Digital Health
Answered on

I would not recommend adjuvant chemotherapy for a postmenopausal woman with 1-3 nodes based on RxPONDER. With an Oncotype of 10, this is an endocrine-sensitive tumor that has favorable prognosis and the key is to start endocrine therapy and plan for extended duration, don’t stop at 5 years for sure....

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
Answered on · Updated on

While Oncotype DX Recurrence Score (ODX-RS) has prognostic and predictive value regarding adjuvant chemotherapy, recent studies have shown the clinical distinctiveness in BRCA1/2–driven early breast cancers or invasive lobular breast cancers, as well as the age being an important factor. There has b...

Join for free or sign in to see the full answer